Company intelligence / Profile preview
Bereum
Wonju, Gangwon-do, South Koreabereum.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Bereum is a South Korean biotechnology company specializing in the research and development of postbiotics, specifically heat-killed lactic acid bacteria. The company's core technology centers on the EF-2001 strain of Enterococcus faecalis, which is processed to maintain high concentrations of effector molecules for immune modulation. Bereum provides high-concentration postbiotic raw materials for the food, cosmetic, and pharmaceutical industries. Their R&D pipeline explores the therapeutic potential of postbiotics in treating inflammatory diseases, atopic dermatitis, and muscle-related conditions.
- Therapeutic areas
- ImmunologyDermatologyMetabolic Disorders
- Modalities
- PostbioticsMicrobial therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Yonsei UniversityHallym University
Beyond the preview
Go deeper on Bereum.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bereum.